Treatment of Hepatitis C

医学 聚乙二醇干扰素 耐受性 利巴韦林 内科学 索福斯布维尔 共感染 丙型肝炎 丙型肝炎病毒 白细胞介素28B 免疫学 不利影响 人类免疫缺陷病毒(HIV) 病毒
作者
Anita Kohli,Ashton A. Shaffer,Amy C Sherman,Shyam Kottilil
出处
期刊:JAMA [American Medical Association]
卷期号:312 (6): 631-631 被引量:437
标识
DOI:10.1001/jama.2014.7085
摘要

IMPORTANCE: Hepatitis C virus (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler therapeutics using direct-acting antivirals that target various stages of the HCV life cycle are in development to eradicate HCV without concomitant interferon. OBJECTIVES: To summarize published evidence on safety, efficacy (measured by a sustained virologic response [SVR], which is the treatment goal of undetectable plasma HCV RNA 12 or 24 weeks after therapy completion), and tolerability of current US Food and Drug Administration-approved interferon-based regimens and oral interferon-free regimens used for treating HCV infection and coinfection with human immunodeficiency virus (HIV) and HCV; to provide treatment recommendations for specialists and generalists based on published evidence. EVIDENCE REVIEW: A literature search of Web of Science, Scopus, Embase, Agricola, Cochrane Library, Cinahl Plus, ClinicalTrials.gov, Conference Papers Index, Gideon, PsycINFO, Google Scholar, and Oaister was conducted from January 1, 2009, to May 30, 2014. Publications describing phase 2, 3, and 4 studies evaluating the treatment of HCV were included. Forty-one studies involving 19,063 adult patients were included. Strength of clinical data and subsequent HCV treatment recommendations were graded according to the Oxford Centre for Evidence-Based Medicine. FINDINGS: Patients infected with HCV genotype 1 represent 60% to 75% of HCV infections in the United States. Hepatitis C virus genotype 1 is more difficult to cure than genotype 2 or genotype 3. Patients with HCV genotype 1 should receive treatment with sofosbuvir + pegylated interferon + ribavirin because of the shorter duration of therapy and high rates of SVR (89%-90%). Simeprevir + pegylated interferon + ribavirin is an alternative for patients with HCV genotype 1 (SVR, 79%-86%). Patients with HCV genotypes 2 and 3, representing 20% to 29% of US HCV infections, should receive therapy with sofosbuvir + ribavirin alone (SVR for genotype 2, 12 weeks' duration: 82%-93%; SVR for genotype 3, 24 weeks' duration, 80%-95%). Patients with HIV-HCV coinfection and patients with compensated cirrhosis (ie, cirrhosis but preserved synthetic liver function) should receive the same treatment as HCV-monoinfected patients. CONCLUSIONS AND RELEVANCE: New, short-duration, simpler therapies result in high SVR rates for HCV-infected patients. In conjunction with increased screening for HCV as suggested by recent Centers for Disease Control and Prevention guidelines, availability of new therapies may lead to the treatment of many more people with chronic HCV infection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
稀西发布了新的文献求助10
1秒前
675675发布了新的文献求助30
1秒前
2秒前
Maestro_S的应助被achilles采纳,获得10
2秒前
乐乐的应助被achilles采纳,获得10
2秒前
阿申爱乐的应助被正直迎夏采纳,获得30
3秒前
ccccc完成签到 ,获得积分10
4秒前
科研通AI65的应助被Lighter采纳,获得10
4秒前
科研通AI6.3的应助被小艾同学采纳,获得10
5秒前
yummy完成签到 ,获得积分10
7秒前
7秒前
啦啦啦完成签到,获得积分10
8秒前
10秒前
乌龙茶发布了新的文献求助10
14秒前
molihuakai的应助被fengfengfeng采纳,获得10
14秒前
14秒前
空白格完成签到 ,获得积分10
15秒前
sun完成签到,获得积分10
16秒前
16秒前
yeo发布了新的文献求助10
16秒前
Coco完成签到,获得积分10
17秒前
18秒前
cc发布了新的文献求助20
19秒前
19秒前
19秒前
落叶完成签到,获得积分10
20秒前
正直迎夏给正直迎夏的求助进行了留言
21秒前
易宋发布了新的文献求助30
21秒前
22秒前
大模型的应助被小贾没有投篮采纳,获得10
22秒前
22秒前
111完成签到,获得积分20
23秒前
Add完成签到 ,获得积分10
24秒前
文世明完成签到,获得积分10
24秒前
孙淳发布了新的文献求助10
24秒前
美女与绿水鬼完成签到,获得积分10
25秒前
王大花完成签到 ,获得积分10
25秒前
25秒前
里予发布了新的文献求助30
26秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598